Submission Details
| 510(k) Number | K093758 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 07, 2009 |
| Decision Date | November 17, 2010 |
| Days to Decision | 345 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
K093758 is an FDA 510(k) clearance for the BGM GALECTIN -3, a Galectin-3 In Vitro Diagnostic Assay (Class II — Special Controls, product code OSX), submitted by Bg Medicine, Inc. (Waltham, US). The FDA issued a Cleared decision on November 17, 2010, 345 days after receiving the submission on December 7, 2009. This device falls under the Chemistry review panel. Regulated under 21 CFR 862.1117.
| 510(k) Number | K093758 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 07, 2009 |
| Decision Date | November 17, 2010 |
| Days to Decision | 345 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
| Product Code | OSX — Galectin-3 In Vitro Diagnostic Assay |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.1117 |
| Definition | Galectin-3 Is Indicated For Use In Conjunction With Clinical Evaluation As An Aid In Assessing The Prognosis Of Patients Diagnosed With Chronic Heart Failure. |